Detalhe da pesquisa
1.
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.
Future Oncol
; 16(15): 991-999, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32250167
2.
Population doubling: a simple and more accurate estimation of cell growth suppression in the in vitro assay for chromosomal aberrations that reduces irrelevant positive results.
Environ Mol Mutagen
; 43(1): 36-44, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-14743344